RYTM
Rhythm Pharmaceuticals, Inc.
NASDAQ · Healthcare · Biotechnology · US
$102.80
−2.00%Aug 17, 2026, 12:00 UTC
Rhythm Pharmaceuticals appointed Manher (AJ) Joshi as Chief Medical Officer, effective August 17, 2026.
Source:Aug 4, 2026, 12:30 UTC
Rhythm Pharmaceuticals announced preliminary data from an ongoing mid-stage study showing its experimental weekly injectable drug reduced body weight in patients with a rare form of obesity caused by brain damage.
Source:Aug 4, 2026, 11:01 UTC
Rhythm Pharmaceuticals reported second quarter 2026 net product revenue of $71.3 million from global sales of IMCIVREE.
Aug 4, 2026, 11:01 UTC
Rhythm Pharmaceuticals reported a strong U.S. launch of IMCIVREE for acquired hypothalamic obesity, with over 400 patient start forms received since FDA approval as of June 30, 2026.
Source:Jun 15, 2026, 16:51 UTC
Rhythm Pharmaceuticals reported preliminary results from an ongoing Phase 2 study evaluating setmelanotide in patients with Prader-Willi syndrome.
Source: